ARK Investment Management LLC Reduces Stock Position in COMPASS Pathways plc (NASDAQ:CMPS)

ARK Investment Management LLC lessened its stake in shares of COMPASS Pathways plc (NASDAQ:CMPS - Free Report) by 13.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,736,202 shares of the company's stock after selling 268,923 shares during the quarter. ARK Investment Management LLC owned approximately 2.54% of COMPASS Pathways worth $6,563,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Sio Capital Management LLC boosted its stake in COMPASS Pathways by 211.7% in the 3rd quarter. Sio Capital Management LLC now owns 914,639 shares of the company's stock worth $5,762,000 after buying an additional 621,222 shares during the last quarter. Rosalind Advisors Inc. boosted its stake in COMPASS Pathways by 6.5% in the 3rd quarter. Rosalind Advisors Inc. now owns 781,423 shares of the company's stock worth $4,923,000 after buying an additional 47,423 shares during the last quarter. Polar Asset Management Partners Inc. boosted its stake in COMPASS Pathways by 83.3% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company's stock worth $3,576,000 after buying an additional 258,000 shares during the last quarter. Acuta Capital Partners LLC acquired a new stake in COMPASS Pathways in the 3rd quarter worth about $2,435,000. Finally, Walleye Capital LLC acquired a new stake in COMPASS Pathways in the 3rd quarter worth about $2,126,000. Hedge funds and other institutional investors own 46.19% of the company's stock.

Remove Ads

Analyst Ratings Changes

A number of analysts have issued reports on CMPS shares. Stifel Nicolaus started coverage on COMPASS Pathways in a research note on Thursday. They issued a "buy" rating and a $11.00 price target on the stock. Royal Bank of Canada reissued an "outperform" rating and issued a $18.00 price target on shares of COMPASS Pathways in a research note on Wednesday, January 15th. HC Wainwright reduced their price objective on COMPASS Pathways from $60.00 to $45.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. Maxim Group reduced their price objective on COMPASS Pathways from $22.00 to $12.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Finally, Canaccord Genuity Group reduced their price objective on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, COMPASS Pathways presently has a consensus rating of "Buy" and a consensus price target of $21.83.

COMPASS Pathways Trading Up 0.3 %

Shares of NASDAQ CMPS traded up $0.01 during midday trading on Friday, hitting $3.93. The stock had a trading volume of 1,247,976 shares, compared to its average volume of 1,273,099. The company has a fifty day moving average price of $4.06 and a 200 day moving average price of $5.26. The company has a market capitalization of $268.89 million, a price-to-earnings ratio of -1.79 and a beta of 2.28. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15. COMPASS Pathways plc has a 1-year low of $3.16 and a 1-year high of $12.57.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.01). On average, analysts predict that COMPASS Pathways plc will post -2.33 earnings per share for the current year.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.